PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-0.28%
Negative ROE while Drug Manufacturers - Specialty & Generic median is 0.89%. Seth Klarman would investigate if capital structure or industry issues are at play.
-0.20%
Negative ROA while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would consider if assets are underutilized or if it’s a distressed opportunity.
0.89%
ROCE of 0.89% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if moderate profitability can widen vs. peers.
51.34%
Gross margin near Drug Manufacturers - Specialty & Generic median of 53.77%. Charlie Munger might attribute it to standard industry practices.
14.33%
Margin of 14.33% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if moderate profitability can be leveraged further.
-3.52%
Negative net margin while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see if cost cuts or revenue growth can fix losses.